Table 2.
Xerostomia associated with coronavirus disease 2019 (COVID-19).
| Subjects | Severity of Disease | Country or Ethnicity | Number of Patients | Mean or Median Age (Range) | Male (%) | Assessment Method | Symptom | Prevalence (%) | Reference |
|---|---|---|---|---|---|---|---|---|---|
| Hospitalized patients diagnosed according to the official guideline and by SARS-CoV-2 nucleic acid detection | Mild to critical | China | 108 | 52.0 (one patient excluded) |
48.1 | Self-reported questionnaire | Dry mouth | 46.3 | Chen et al. [9] * |
| Ambulatory non-hospitalized patients (quarantined in hotel) diagnosed by RT-PCR test | Mild | Israel | 128 | 36.3 (18–73) |
45.3 | Self-reported web-based questionnaire | Xerostomia | 56.3 | Biadsee et al. [65] * |
| Patients diagnosed by RT-PCR test | NS | European 88% Asian 12% |
50 | 37.7 (18–65) |
60.0 | Self-reported questionnaire | Xerostomia | 32.0 | Freni et al. [80] * |
| Patients diagnosed by real-time RT-PCR test | NS | Italy | 111 | 57 (48–67) |
52.3 | Self-reported questionnaire to rate xerostomia scores | Xerostomia | 45.9 | Fantozzi et al. [112] * |
* indicates studies that were used to characterize symptom prevalence in discussion. NS: not specified.